Last reviewed · How we verify

NCT00228904

Effects of Pulsatile IV Insulin Delivery on Peripheral Diabetic Neuropathy

Withdrawn Phase 2/Phase 3 Last updated 8 August 2016
What this trial tests

Phase 2/Phase 3 trial testing Placebo in Diabetic Neuropathy. Withdrawn.

Timeline
1 February 2005
Primary endpoint
1 May 2011
1 October 2011

Quick facts

Lead sponsorFlorida Atlantic University
PhasePhase 2/Phase 3
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Start date1 February 2005
Primary completion1 May 2011
Estimated completion1 October 2011
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Florida Atlantic University

Who can join

Adults 20 to 90, any sex, with Diabetic Neuropathy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Diabetic neuropathy is a progressive complication causing serious problems in 25-40% of diabetic patients. Anecdotal reports have indicated improvement with pulsatile IV insulin therapy in affected patients otherwise resistant to all conventional therapies. Significant complications produce painful peripheral dysesthesias, loss of sensation and gastroparesis. This study is designed to test the effectiveness of pulsatile IV insulin therapy on diabetic neuropathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Neuropathy

Currently open trials in the same condition.

Other Florida Atlantic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00228904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing